Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care Platelet Function Assay-100 C/ADP

American Heart Journal

Volumn 159, Issue 3, 2010, Pages 434-438

  Moerenhout, Catherine M ^a   Claeys, Marc J ^a   Haine, Steven ^a   Miljoen, Hielko ^a   Bosmans, Johan M ^a   Vertessen, Francine ^a   Kluppels, Katrien ^a   Van der Planken, Marc ^a   Vrints, Christiaan J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CELL ASSAY; CONTROLLED STUDY; CORONARY STENT; DRUG DOSE TITRATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY VESSELS; DEATH, SUDDEN, CARDIAC; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 77649134380     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.12.020     Document Type: Article

References (28)

1. Gawaz M., Neumann F.J., Ott I., et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 94 (1996) 279-285
2. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
3. Claeys M.J. Antiplatelet therapy for elective coronary stenting: a moving target. Semin Vasc Med 3 (2003) 415-418
4. Kuliczkowski W., Witkowski A., Polonski L., et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30 (2009) 426-435 Epub 2009 Jan 27
5. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362 Epub 2008 Dec
6. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913 Epub 2003 Jun 9
7. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52 (2008) 734-739
8. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
9. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750 Epub 2006 Oct 1
10. Mammen E.F., Comp P.C., Gosselin R., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 (1998) 195-202
11. Van der Planken M.G., Claeys M.J., Vertessen F.J., et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 111 (2003) 159-164
12. Claeys M.J., Van der Planken M.G., Michiels J.J., et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis 13 (2002) 283-288
13. Claeys M.J., Van der Planken M.G., Bosmans J.M., et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J 26 (2005) 567-575 Epub 2004 Dec 16
14. Cavallini C., Savonitto S., Violini R., et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 26 (2005) 1494-1498 Epub 2005 Mar 1
15. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. Eur Heart J 28 (2007) 2525-2538
16. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
17. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
18. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33 Epub 2005 Dec 9
19. Paniccia R., Antonucci E., Gori A.M., et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5 (2007) 1839-1847
20. Lordkipanidze M., Pharand C., Nguyen T.A., et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 29 (2008) 2877-2885 Epub 2008 Sep 30
21. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000 Epub 2008 Feb 10
22. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
23. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
24. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106 Epub 2005 Mar 6
25. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173 Epub 2006 Apr 18
26. Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047 Epub 2006 Feb 13
27. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
28. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564 Epub 2005 Apr 4